relpax 40 mg tablet
viatris healthcare (pty) ltd - tablet - see ingredients - each tablet contains eletriptan hydrobromide equivalent to eletriptan 40,0 mg
relpax 80 mg tablet
viatris healthcare (pty) ltd - tablet - see ingredients - each tablet contains eletriptan hydrobromide equivalent to eletriptan 80,0 mg
relpax® 40mg 40mg / tablet
ahmed khalil al baker medical supplies italy - 3's (3's blister x 1) - tablet - 40mg / tablet - central nervous system-analgesics
relpax® 40mg
3's (3's blister x 1) -
relpax film coated tab 20 mg
مستودع ادوية الصباغ - sabbagh drug store - eletriptan 20 mg - 20 mg
relpax film coated tab 20 mg
مستودع ادوية الصباغ - sabbagh drug store - eletriptan 20 mg - 20 mg
relpax 20 mg
pfizer laboratories (pty) ltd - eletriptan - tablets - eletriptan tablets 20mg
relpax 40 mg
pfizer laboratories (pty) ltd - eletriptan - tablets - eletriptan tablets 40mg
relpax 80 mg
pfizer laboratories (pty) ltd - eletriptan - tablets - eletriptan tablets 80mg
naratriptan tablet
heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - naratriptan hydrochloride (unii: 10x8x4p12z) (naratriptan - unii:qx3kxl1za2) - naratriptan 1 mg - naratriptan tablets are indicated for the acute treatment of migraine with or without aura in adults. limitations of use: - use only if a clear diagnosis of migraine has been established. if a patient has no response to the first migraine attack treated with naratriptan tablets reconsider the diagnosis of migraine before naratriptan tablets are administered to treat any subsequent attacks. - naratriptan tablets are not indicated for the prevention of migraine attacks. - safety and effectiveness of naratriptan tablets have not been established for cluster headache. naratriptan tablets are contraindicated in patients with: - ischemic coronary artery disease (cad) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including prinzmetal's angina [see warnings and precautions (5.1) ] - wolff-parkinson-white syndrome or arrhythmias associated with other cardiac accessory conduction pathway d